%0 Journal Article
%T A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study
%A Suzanne Dunne
%A Bill Shannon
%A Colum Dunne
%A Walter Cullen
%J BMC Pharmacology and Toxicology
%D 2013
%I BioMed Central
%R 10.1186/2050-6511-14-1
%X Generic medicines are those where the original patent has expired and which may now be produced by manufacturers other than the original innovator (patent-holding) company. The term ¡°generic drug¡±a or ¡°generic medicine¡± can have varying definitions in different markets, however the term is commonly understood, as defined by the World Health Organisation (WHO), to mean a pharmaceutical product which:¨C is usually intended to be interchangeable with an innovator product,¨C is manufactured without a licence from the innovator company, and¨C is marketed after the expiry date of the patent or other exclusive rights [1].There are differing legal requirements in different jurisdictions that define the specifics of what a generic medicine is. However, one of the main principles underpinning the safe and effective use of generic medicines is the concept of bioequivalence.Bioequivalence has been defined as follows: two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards[2].The purpose of establishing bioequivalence is to demonstrate equivalence between the generic medicine and the originator medicine in order to allow bridging of the pre-clinical and clinical testing performed on the originator drug.The objective of this article is to provide an accessible resource describing the foundation of generic medicines, from their legal advent in the mid 1980¡¯s to how current legislation and regulation of generics affects, inter alia, their composition, regulatory approval, pricing, and ultimately acceptance by healthcare professiona
%K Generic
%K Medicine
%K Drug
%K Pharmaceutical
%K Biosimilar
%K Prescribing
%K Healthcare
%K Economics
%K Ireland
%U http://www.biomedcentral.com/2050-6511/14/1